Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C8H12N4O5 |
Molecular Weight | 244.2047 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)C1=NN(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O
InChI
InChIKey=IWUCXVSUMQZMFG-AFCXAGJDSA-N
InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
Molecular Formula | C8H12N4O5 |
Molecular Weight | 244.2047 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adf16e64-345f-469a-b987-3fbdd17e0ac2 |
http://www.news-medical.net/health/Ribavirin-History.aspx
Curator's Comment: description was created based on several sources, including
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adf16e64-345f-469a-b987-3fbdd17e0ac2 |
http://www.news-medical.net/health/Ribavirin-History.aspx
Ribavirin is a synthetic nucleoside analogue, which was first discovered and developed in 1970 by researchers from the International Chemical & Nuclear Corporation (ICN), today known as Valeant Pharmaceuticals. Ribavirin was initially approved for use in humans to treat pediatric respiratory syncytial virus infections (RSV). In cell cultures the inhibitory activity of ribavirin for RSV is selective. The mechanism of action is unknown. Reversal of the in vitro antiviral activity by guanosine or xanthosine suggests ribavirin may act as an analogue of these cellular metabolites. There were no other significant advancements in the treatment of hepatitis C until 1998, when the combination of ribavirin and interferon-alpha gained approval. Clinically, ribavirin showed a small, additive antiviral effect in combination with interferon, but its main effect was dose-dependent prevention of virological relapse. The mechanism by which the combination of ribavirin and an interferon product exerts its effects against the hepatitis C virus has not been fully established. However, it could be thorough the inhibition of inosine monophosphate dehydrogenase (IMPDH), which is the key step in de novo guanine synthesis, a requirement for viral replication.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1822 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16293677 |
|||
Target ID: CHEMBL5375 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16107837 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VIRAZOLE Approved UseVIRAZOLE (Ribavirin for Inhalation Solution, USP) is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus. Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy. Only severe RSV lower respiratory tract infection should be treated with VIRAZOLE. The vast majority of infants and children with RSV infection have disease that is mild, self-limited, and does not require hospitalization or antiviral treatment. Many children with mild lower respiratory tract involvement will require shorter hospitalization than would be required for a full course of VIRAZOLE aerosol (3 to 7 days) and should not be treated with the drug. Thus the decision to treat with VIRAZOLE should be based on the severity of the RSV infection. The presence of an underlying condition such as prematurity, immunosuppression or cardiopulmonary disease may increase the severity of clinical manifestations and complications of RSV infection. Use of aerosolized VIRAZOLE in patients requiring mechanical ventilator assistance should be undertaken only by physicians and support staff familiar with this mode of administration and the specific ventilator being used Launch Date5.04835211E11 |
|||
Primary | COPEGUS Approved UseCOPEGUS in combination with PEGASYS (peginterferon alfa-2a) is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A). Launch Date1.03887359E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3680 ng/mL |
600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
RIBAVIRIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
228000 ng × h/mL |
600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
RIBAVIRIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
298 h |
600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
RIBAVIRIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 21 years n = 1 Health Status: unhealthy Condition: respiratory syncytial virus (RSV) infection Age Group: 21 years Sex: M Population Size: 1 Sources: |
Disc. AE: Hyperuricemia, Injury to kidney... AEs leading to discontinuation/dose reduction: Hyperuricemia (severe, 1 patient) Sources: Injury to kidney (acute, 1 patient) |
2400 mg 1 times / day multiple, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: multiple Dose: 2400 mg, 1 times / day Sources: |
unhealthy, 39.9 years (range: 27 - 51 years) n = 3 Health Status: unhealthy Condition: generalized lymphadenopathy Age Group: 39.9 years (range: 27 - 51 years) Sex: M Population Size: 3 Sources: |
Disc. AE: Nausea, Vomiting... Other AEs: CNS disorder (NOS), Fatigue... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Other AEs:Vomiting (1 patient) Headache (severe, 1 patient) Hematocrit low (1 patient) CNS disorder (NOS) (severe, 3 patients) Sources: Fatigue (3 patients) |
16 mg/kg 4 times / day multiple, intravenous Highest studied dose Dose: 16 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 16 mg/kg, 4 times / day Sources: |
unhealthy, 6-10 years n = 2 Health Status: unhealthy Condition: La Crosse viral encephalitis Age Group: 6-10 years Sex: F Population Size: 2 Sources: |
Disc. AE: Nonprotein nitrogen blood increased, Abdominal pain... AEs leading to discontinuation/dose reduction: Nonprotein nitrogen blood increased (1 patient) Sources: Abdominal pain (1 patient) Tenderness (1 patient) Anorexia (1 patient) Pancreatic enzymes increased (1 patient) Pancreatitis (1 patient) |
1200 mg 1 times / day multiple, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
pregnant Health Status: pregnant Sources: |
Other AEs: Fetal death... Other AEs: Fetal death (grade 5) Sources: |
1200 mg 1 times / day multiple, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: chronic hepatitis C virus infection Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Injury to kidney | acute, 1 patient Disc. AE |
600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 21 years n = 1 Health Status: unhealthy Condition: respiratory syncytial virus (RSV) infection Age Group: 21 years Sex: M Population Size: 1 Sources: |
Hyperuricemia | severe, 1 patient Disc. AE |
600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 21 years n = 1 Health Status: unhealthy Condition: respiratory syncytial virus (RSV) infection Age Group: 21 years Sex: M Population Size: 1 Sources: |
Hematocrit low | 1 patient Disc. AE |
2400 mg 1 times / day multiple, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: multiple Dose: 2400 mg, 1 times / day Sources: |
unhealthy, 39.9 years (range: 27 - 51 years) n = 3 Health Status: unhealthy Condition: generalized lymphadenopathy Age Group: 39.9 years (range: 27 - 51 years) Sex: M Population Size: 3 Sources: |
Nausea | 1 patient Disc. AE |
2400 mg 1 times / day multiple, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: multiple Dose: 2400 mg, 1 times / day Sources: |
unhealthy, 39.9 years (range: 27 - 51 years) n = 3 Health Status: unhealthy Condition: generalized lymphadenopathy Age Group: 39.9 years (range: 27 - 51 years) Sex: M Population Size: 3 Sources: |
Vomiting | 1 patient Disc. AE |
2400 mg 1 times / day multiple, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: multiple Dose: 2400 mg, 1 times / day Sources: |
unhealthy, 39.9 years (range: 27 - 51 years) n = 3 Health Status: unhealthy Condition: generalized lymphadenopathy Age Group: 39.9 years (range: 27 - 51 years) Sex: M Population Size: 3 Sources: |
Fatigue | 3 patients | 2400 mg 1 times / day multiple, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: multiple Dose: 2400 mg, 1 times / day Sources: |
unhealthy, 39.9 years (range: 27 - 51 years) n = 3 Health Status: unhealthy Condition: generalized lymphadenopathy Age Group: 39.9 years (range: 27 - 51 years) Sex: M Population Size: 3 Sources: |
Headache | severe, 1 patient Disc. AE |
2400 mg 1 times / day multiple, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: multiple Dose: 2400 mg, 1 times / day Sources: |
unhealthy, 39.9 years (range: 27 - 51 years) n = 3 Health Status: unhealthy Condition: generalized lymphadenopathy Age Group: 39.9 years (range: 27 - 51 years) Sex: M Population Size: 3 Sources: |
CNS disorder (NOS) | severe, 3 patients | 2400 mg 1 times / day multiple, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: multiple Dose: 2400 mg, 1 times / day Sources: |
unhealthy, 39.9 years (range: 27 - 51 years) n = 3 Health Status: unhealthy Condition: generalized lymphadenopathy Age Group: 39.9 years (range: 27 - 51 years) Sex: M Population Size: 3 Sources: |
Abdominal pain | 1 patient Disc. AE |
16 mg/kg 4 times / day multiple, intravenous Highest studied dose Dose: 16 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 16 mg/kg, 4 times / day Sources: |
unhealthy, 6-10 years n = 2 Health Status: unhealthy Condition: La Crosse viral encephalitis Age Group: 6-10 years Sex: F Population Size: 2 Sources: |
Anorexia | 1 patient Disc. AE |
16 mg/kg 4 times / day multiple, intravenous Highest studied dose Dose: 16 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 16 mg/kg, 4 times / day Sources: |
unhealthy, 6-10 years n = 2 Health Status: unhealthy Condition: La Crosse viral encephalitis Age Group: 6-10 years Sex: F Population Size: 2 Sources: |
Nonprotein nitrogen blood increased | 1 patient Disc. AE |
16 mg/kg 4 times / day multiple, intravenous Highest studied dose Dose: 16 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 16 mg/kg, 4 times / day Sources: |
unhealthy, 6-10 years n = 2 Health Status: unhealthy Condition: La Crosse viral encephalitis Age Group: 6-10 years Sex: F Population Size: 2 Sources: |
Pancreatic enzymes increased | 1 patient Disc. AE |
16 mg/kg 4 times / day multiple, intravenous Highest studied dose Dose: 16 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 16 mg/kg, 4 times / day Sources: |
unhealthy, 6-10 years n = 2 Health Status: unhealthy Condition: La Crosse viral encephalitis Age Group: 6-10 years Sex: F Population Size: 2 Sources: |
Pancreatitis | 1 patient Disc. AE |
16 mg/kg 4 times / day multiple, intravenous Highest studied dose Dose: 16 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 16 mg/kg, 4 times / day Sources: |
unhealthy, 6-10 years n = 2 Health Status: unhealthy Condition: La Crosse viral encephalitis Age Group: 6-10 years Sex: F Population Size: 2 Sources: |
Tenderness | 1 patient Disc. AE |
16 mg/kg 4 times / day multiple, intravenous Highest studied dose Dose: 16 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 16 mg/kg, 4 times / day Sources: |
unhealthy, 6-10 years n = 2 Health Status: unhealthy Condition: La Crosse viral encephalitis Age Group: 6-10 years Sex: F Population Size: 2 Sources: |
Fetal death | grade 5 | 1200 mg 1 times / day multiple, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
pregnant Health Status: pregnant Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no |
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis of tetrazole ribonucleosides and their evaluation as antiviral agents. | 1976 Feb |
|
Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. | 1976 Mar |
|
Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines. | 1992 Aug 21 |
|
Selective inhibition of arthropod-borne and arenaviruses in vitro by 3'-fluoro-3'-deoxyadenosine. | 1992 Jun |
|
(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties. | 1992 Jun 12 |
|
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives. | 1992 Nov 27 |
|
Ribavirin--current status of a broad spectrum antiviral agent. | 2001 Aug |
|
Inhibition of measles virus replication by 5'-nor carbocyclic adenosine analogues. | 2001 Jul |
|
The in vitro study of influence of four novel platinum compounds on rodent melanoma cells. | 2001 May-Jun |
|
In vitro evaluation of secoiridoid glucosides from the fruits of Ligustrum lucidum as antiviral agents. | 2001 Nov |
|
Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study. | 2001 Oct |
|
Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin. | 2001 Sep 28 |
|
[ROC curve analysis of factors predictive of response to treatment with interferon plus ribavirin in patients with chronic hepatitis C relapse after previous interferon treatment]. | 2002 Dec |
|
Antiviral activity of brassinosteroids derivatives against measles virus in cell cultures. | 2002 Jan |
|
Effect of ribavirin on epididymal sperm count in rat. | 2002 Jan |
|
Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. | 2002 Jan |
|
Identification of active antiviral compounds against a New York isolate of West Nile virus. | 2002 Jul |
|
Cidofovir in the treatment of poxvirus infections. | 2002 Jul |
|
Interferon-alpha induced transient thyroid dysfunction in hepatitis C. | 2002 Mar |
|
Evaluation of the antiviral activity against Junin virus of macrocyclic trichothecenes produced by the hypocrealean epibiont of Baccharis coridifolia. | 2002 Mar |
|
Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. | 2002 May |
|
Inhibition of the replication of a hepatitis C virus-like RNA template by interferon and 3'-deoxycytidine. | 2002 Nov |
|
Inhibitors of the IMPDH enzyme as potential anti-bovine viral diarrhoea virus agents. | 2002 Nov |
|
The quest for an efficacious antiviral for respiratory syncytial virus. | 2002 Nov |
|
Search of antimicrobial activity of selected non-antibiotic drugs. | 2002 Nov-Dec |
|
Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds. | 2002 Oct |
|
Treatment of acute hepatitis C virus infection with interferon-alpha 2b and ribavirin: case report and review of the literature. | 2002 Oct 14 |
|
U.S. veterans' experience with rebetron in a nonstudy environment: success or failure? | 2002 Sep |
|
Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. | 2002 Sep |
|
Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. | 2002 Sep |
|
Anemia in the treatment of hepatitis C virus infection. | 2003 |
|
Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats. | 2003 Apr 15 |
|
Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. | 2003 Aug |
|
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. | 2003 Aug |
|
Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon. | 2003 Aug 15 |
|
[Is chronic hepatitis C treatment as efficient in the general population as in randomised trials?]. | 2003 Aug-Sep |
|
Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia. | 2003 Feb |
|
Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. | 2003 Feb |
|
In vitro activity of potential anti-poxvirus agents. | 2003 Jan |
|
[52-year-old patient with subcutaneous space-occupying lesion in immunosuppression]. | 2003 Jun |
|
Correlation of sICAM-1 and sVCAM-1 level with biochemical, histological and viral findings in chronic hepatitis C after interferon-alpha + ribavirin therapy. | 2003 Jun |
|
Severe migraine headaches are caused by ribavirin but not by interferon alpha-2B in combination therapy for chronic hepatitis C. | 2003 Jun |
|
Ribavirin and alpha interferon enhance death receptor-mediated apoptosis and caspase activation in human hepatoma cells. | 2003 Jun |
|
A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C. | 2003 Jun |
|
Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. | 2003 Mar |
|
How can we identify better those with recurrent hepatitis C who will respond to therapy? What are the optimal treatment regimen and treatment duration? | 2003 Nov |
|
Rosacea fulminans associated with pegylated interferon alpha-2B and ribavirin therapy. | 2003 Oct |
|
Intracerebral haemorrhage and hepatitis C treatment. | 2003 Sep |
|
Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. | 2003 Sep-Oct |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adf16e64-345f-469a-b987-3fbdd17e0ac2
respiratory syncytial virus infection: 20 mg/mL VIRAZOLE (Ribavirin for inhalation solution) as the starting solution in the drug reservoir of the SPAG-2 unit, with continuous aerosol administration for 12-18 hours per day for 3 to 7 days. Using the recommended drug concentration of 20 mg/mL the average aerosol concentration for a 12 hour delivery period would be 190 micrograms/liter of air. Aerosolized VIRAZOLE should not be administered in a mixture for combined aerosolization or simultaneously with other aerosolized medications.
Chronic hepatitis C virus infection: The recommended duration of treatment for patients previously untreated with ribavirin and interferon is 24 to 48 weeks. The daily dose of COPEGUS (ribavirin) tablets is 800 mg to 1200 mg administered orally in two divided doses. The dose should be individualized to the patient depending on baseline disease characteristics (eg, genotype), response to therapy, and tolerability of the regimen.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12719586
To determine the optimal concentration and timing of ribavirin treatment for the inhibition of viral transcription, Human A549 pulmonary type II epithelial cells pretreated (2 h) or posttreated (1 h) with increasing concentrations of ribavirin (from10 to 100 microg/ml) were exposed to pRSV (Respiratory syncytial virus). Total cellular RNA was harvested 36 h later, and the abundance of the 1.1-kb RSV N transcript was measured by Northern blotting. Ribavirin treatment potently inhibited RSV transcription, thereby reducing the level of RSV N transcripts to approximately 13% of levels in nontreated cells. In RSV-infected epithelial cells, ribavirin reduces plaque formation, the release of infectious virions, and F glycoprotein expression.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:35:07 UTC 2023
by
admin
on
Fri Dec 15 15:35:07 UTC 2023
|
Record UNII |
49717AWG6K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175466
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
RIBAVIRIN TEVA (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
WHO-ATC |
J05AP01
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
FDA ORPHAN DRUG |
57491
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
RIBAVIRIN TEVA PHARMA B.V. (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
LIVERTOX |
NBK548115
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
WHO-VATC |
QJ05AB04
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
COTRONAK (REFUSED: HEPATITIS C, CHRONIC)
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
NDF-RT |
N0000175459
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/01/024
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.3
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
NCI_THESAURUS |
C281
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
REBETOL (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
WHO-ATC |
J05AB04
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
NDF-RT |
N0000175459
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
NDF-RT |
N0000175459
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
RIBAVIRIN BIOPARTNERS (WITHDRAWN: HEPATITIS C, CHRONIC)
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
FDA ORPHAN DRUG |
162402
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
RIBAVIRIN MYLAN (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
163039
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
C807
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
3543
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
CHEMBL1643
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
100000089166
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
D012254
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
36791-04-5
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
1602706
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
SUB10297MIG
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
COPEGUS
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | APPROVED MARCH 2015 | ||
|
Ribavirin
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
m9593
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | Merck Index | ||
|
DTXSID8023557
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
63580
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
DB00811
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
6513
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
ribavirin
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
6842
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
66510-90-5
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
SUPERSEDED | |||
|
9344
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | RxNorm | ||
|
RIBAVIRIN
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
49717AWG6K
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
2373
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
37542
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY | |||
|
49717AWG6K
Created by
admin on Fri Dec 15 15:35:07 UTC 2023 , Edited by admin on Fri Dec 15 15:35:07 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
TARGET ORGANISM->INHIBITOR |
A guanine derivative approved for treating HCV and respiratory syncytial virus (RSV) that has been evaluated in patients with SARS and MERS, but its side effects such as anaemia may be severe at high doses.
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
a degradative pathway involving deribosylation and amide hydrolysis to yield a triazole carboxylic acid metabolite; Excreted renally
|
||
|
METABOLITE -> PARENT |
BY adenosine kinase
|
||
|
METABOLITE -> PARENT |
a degradative pathway involving deribosylation and amide hydrolysis to yield a triazole carboxylic acid metabolite; excreted renally.
|
||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT |
by the successive action of nucleoside mono- and di-phosphate kinases
MAJOR
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 2.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|